Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04629547 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sleep Trial to Prevent Alzheimer's Disease

Study acronym: SToP-AD
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Sponsor changed: Washington University School of Medicine to University of Minnesota
    • Site contact updated
    v27
  2. Enrollment reduced: 200 → 120 participantsv26
  3. Primary and study completion dates: May 2026 to May 2028v25
  4. Secondary endpoints: details revised at 11 of 11 entries
    • Site contact updated
    v24
  5. Eligibility criteria shortened, about 16 wordsv23
Show 21 earlier versionsHide 21 earlier versions
  1. Site contact updated
    • Eligibility criteria shortened, about 1 word
    v22
  2. Site contact updated
    • Eligibility criteria shortened, about 4 words
    v21
  3. Collaborators revised (2)v20
  4. Eligibility criteria revisedv19
  5. Eligibility criteria shortened, about 1 wordv18
  6. Primary endpoint revised
    • Eligibility criteria expanded, about 4 words
    • Study description shortened, about 2 words
    v17
  7. Primary endpoint revised
    • Eligibility criteria shortened, about 164 words
    • Secondary endpoints: 12 to 11
    v16
  8. Eligibility criteria expanded, about 33 wordsv15
  9. Eligibility criteria revisedv14
  10. Eligibility criteria expanded, about 13 words
    • Collaborators expanded, about 8 words
    v13
  11. Eligibility criteria shortened, about 2 wordsv12
  12. Start date changed from estimate of May 2022 to May 25, 2022v11
  13. Start date: Mar 2022 to May 2022
    • Primary and study completion dates: Mar 2026 to May 2026
    v10
  14. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v9
  15. Primary and study completion dates: Jan 2025 to Mar 2026
    • Start date: Nov 2021 to Mar 2022
    v8
  16. Start date: Sep 2021 to Nov 2021
    • Eligibility criteria expanded, about 27 words
    • Secondary endpoints: 5 to 12
    v7
  17. Start date: Jul 2021 to Sep 2021v6
  18. Start date: Jun 2021 to Jul 2021
    • Eligibility criteria expanded, about 36 words
    • Secondary endpoints: 4 to 5
    v5
  19. Start date: Jan 2021 to Jun 2021v4
  20. 2 versions Re-verified since Nov 15, 2020, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.
Trial Details
NCT Number NCT04629547
Lead Sponsor University of Minnesota
Collaborators: Good Ventures, Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Sleep, Alzheimer Disease
Related terms Alzheimer Disease, Plaque, Amyloid, Sleep Initiation and Maintenance Disorders
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov